Melissa Thompson, PhDUniversity of Texas MD Anderson Cancer Center The Role of the Tumor Microenvironment in Ovarian Cancer Progression Ovarian cancer is the deadliest gynecological cancer, accounting for 15,520 deaths annually. Preliminary studies by Dr. Thompson indicate that the tumor microenvironment enables and promotes tumor progression and chemoresistance, possibly through the expression of SFRP2. With […]
Read More
Zhiyong Ding, PhDThe University of Texas MD Anderson Cancer Center Identification of novel interaction partners of p110 and p85 in ovarian cancer cells Ovarian cancer, like all cancer, is a disease of gene malfunctions. This study will look at a gene known to control cancer cells (PIK3CA) and the proteins it interacts with. These proteins […]
Read More
Yunfei Wen, PhDUniversity of Texas MD Anderson Cancer Center Suicidal Autophagy: Targeting Tumoral PRL/PRLR Axis in Ovarian Cancer G129R, a molecular antagonist to tumoral PRLR, robustly inhibits tumor growth through formation of excessive autophagosomes in ovarian cancer cells. Dr. Wen will explore the regulatory mechanism of G129R-induced autophagy in ovarian cancer cells and therapeutically evaluate […]
Read More
Kwong-Kwok Wong, PhDUniversity of Texas MD Anderson Cancer Center Targeted Therapy for Ovarian Clear Cell Carcinoma Patients with late stage clear cell ovarian carcinoma have poorer survival rates than the more common high-grade serous ovarian carcinomas. Current therapies are not effective for this aggressive cancer. Dr. Wong‘s preliminary data suggests that targeting the mTOR pathway, […]
Read More
Lilie Lin, MDUniversity of Pennsylvania School of Medicine Pilot study of a novel PARP inhibitor PET tracer in patients with ovarian carcinoma Targeted agents such as poly-ADP ribose polymerase (PARP) inhibitors are actively being tested alone or in combination with chemotherapy or radiotherapy as promising treatments for ovarian cancer. However, not all patients will respond […]
Read More